Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of solifenacin + mirabegron combinations in overactive bladder
NL-OMON36058Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Dec 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solifenacin and mirabegron in overactive bladder (OAB) (12 arms), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in mean volume voided per micturition after 12 weeks of treatment. Started Dec 2011; status: recruiting.
02
Drugs
solifenacinmirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NL-OMON36058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36058.